Gynecological cancers are characterized by uncontrolled growth and spread of abnormal cells. These cancers originate in the female reproductive organs such as uterus, cervix, ovaries, vagina and vulva. Several factors are responsible for the occurrence of these cancers. It includes various classes of cancer originating genes, known as oncogenes, which promotes the abnormal growth of cells. The abnormal function of these genes regulates through aging, smoking and environmental influences. In addition, infertility, obesity, mutations, early start of menstruation and late start of menopause also causes gynecological cancers. Gynecological cancers are also originated by some viruses. For instance, almost all cervical cancers and vaginal and vulva cancers are caused by human papillomavirus (HPV). These gynecological cancers are treated by medication therapies, radiation therapy, surgeries and chemotherapy. Treatments of these cancers are depends upon the type and different stages of cancers.
The global gynecological cancers market is categorized based on various types of cancers and their treatment therapies. It includes uterine, ovarian cancer, vaginal cancer, vulvar cancer and cervical cancer.
Uterine cancer is also known as endometrial cancer. It is the most common type of gynecologic cancer. Major risk factors of uterine cancer include the use of estrogen without progesterone, hypertension, diabetes, tamoxifen, obesity and later age of menopause. Obese women have higher circulating levels of estrogen, which increases their risk for uterine cancer. Cervical cancer is the second most common type of gynecological cancer. Ovarian cancer is mainly divided into three types: germ cell cancer, epithelial ovarian cancer and stromal ovarian cancer. Vulvar and vaginal cancers are rarest forms of gynecological cancer. It usually affects women with age group of 50-70 years.
In terms of geographic, North America and Europe dominates the global gynecological cancers market. The U.S. represents the largest market for gynecological cancers followed by Canada in North America. In Europe, France, Germany and the U.K. holds major share of gynecological cancers market. However, Asia is expected to show high growth rates in the next five years in global gynecological cancers market. This is due to increasing awareness among people about various types of gynecological cancers in the region. Japan, China and India are expected to be the fastest growing gynecological cancers markets in Asia.
Request Sample Report@ https://www.persistencemarketresearch.com/samples/3482
In recent time, increasing prevalence of gynecological cancers is key driver for the global gynecological cancers market. In addition, various government initiatives are also supporting in growth of the global gynecological cancers market. Several government associations have launched various programs to raise awareness among people about these cancers. Moreover, governments provide grant and funds to increase research in oncology field to develop innovative medicines and therapies for their treatment.
However, patent expiry of various major drugs is key restraint for the global gynecological cancers market. In addition, stringent regulatory hurdles also obstruct the growth of global gynecological cancers market. Advancement in personalized medicines holds immense potential for the growth of global gynecological cancers market. Increasing mergers and acquisitions between drugs manufacturing companies and government bodies is key trend of global gynecological cancers market.
Request For Report Table of Content (TOC): https://www.persistencemarketresearch.com/toc/3482
Some of the major companies operating in the global gynecological cancers market are GlaxoSmithKline plc, Becton Dickinson and Co., Eli Lilly and Co., Bristol Myers Squibb Co. and F. Hoffmann La Roche Ltd.